Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMO | Q99835 | 13/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9968399 | 0.92 | MEN1 (0.41) | MEN1KMT2ASMOKDRPLK1 | |
| SCHEMBL9968360 | 0.90 | SMO (0.38) | MEN1KMT2ASMO | |
| SCHEMBL9933504 | 0.89 | KDM4E (0.41) | MEN1KMT2ASMOKDM4ENPC1 | |
| SCHEMBL9932601 | 0.87 | ADRB1 (0.44) | MEN1KMT2ASMOKDM4ENPC1 | |
| SCHEMBL9931663 | 0.83 | KDM4E (0.42) | MEN1KMT2ASMOKDM4ENPC1 | |
| SCHEMBL9968319 | 0.82 | MEN1 (0.46) | MEN1KMT2ASMOKDM4ENPC1 | |
| SCHEMBL9932576 | 0.81 | BRD4 (0.47) | MEN1KMT2ASMOKDRPTK2 | |
| SCHEMBL9932075 | 0.80 | MEN1 (0.41) | MEN1KMT2ASMOKDM4ENPC1 | |
| SCHEMBL9933020 | 0.80 | MEN1 (0.41) | MEN1KMT2ASMOKDM4ENPC1 | |
| SCHEMBL9931789 | 0.80 | PTPN11 (0.43) | MEN1KMT2ASMOKDRPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | MEN1 1168/4885KMT2A 310/4885SMO 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.